Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Stock Short Interest Report for September

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) saw a large decrease in short interest during the month of September. As of September 30th, there was short interest totaling 5,591 shares, a decrease of 93.8% from the September 15th total of 90,785 shares. Based on an average trading volume of 21,117 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the shares of the stock are short sold.

Cyclacel Pharmaceuticals Stock Performance

Shares of NASDAQ:BGMS traded up $0.03 during midday trading on Friday, hitting $0.85. 14,672 shares of the stock were exchanged, compared to its average volume of 175,995. The business’s 50-day moving average price is $0.90 and its 200 day moving average price is $0.94. Cyclacel Pharmaceuticals has a 12 month low of $0.57 and a 12 month high of $6.70. The stock has a market capitalization of $4.69 million, a price-to-earnings ratio of -0.23 and a beta of -0.39.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $0.34 million during the quarter. Cyclacel Pharmaceuticals had a negative net margin of 118.27% and a negative return on equity of 31.60%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Cyclacel Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Cyclacel Pharmaceuticals currently has an average rating of “Sell”.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing targeted medicines for the treatment of cancer. Its research programs center on small-molecule therapies designed to interfere with key cell-cycle and transcription processes involved in tumor growth.

The company’s pipeline has included fadraciclib (CYC065), an oral cyclin-dependent kinase inhibitor being studied for advanced solid tumors and hematologic malignancies. Cyclacel has also developed sapacitabine (CYC682), an oral nucleoside analog, and seliciclib (CYC202), an earlier-stage cyclin-dependent kinase inhibitor.